Answers are grounded in this paper and cite their sources.
Good pharmaceutical innovation policy requires good data about R&D costs. By looking at the economics of the pharmaceutical R&D process, with the use of accurate data about costs, risks, and returns, policymakers can more accurately respond to competing claims for access and incentives to innovate and find ways of promoting affordable, accessible, and innovative drugs while discouraging redundant investments in high cost, low value added drugs. If our pharmaceutical innovation policy goal is truly to make positive contributions to public health, this kind of data should be readily available in usable forms for all drugs and should be used to inform public spending and the design of regulatory incentives.
No takes yet. Share an insight, caveat, or question.
Liza Vertinsky (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: